Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Subsequent Events (Narrative) (Details) - Subsequent Event € / shares in Units, € in Billions, $ in Billions	Apr. 23, 2018 EUR (€) € / shares	Apr. 16, 2018 USD ($)
Rare Disease
Subsequent Event [Line Items]
Agreement consideration \| $		$ 2.4
Takeda
Subsequent Event [Line Items]
Potential offer share price (in usd per share) \| € / shares	€ 49
Potential offer \| €	€ 46